Why the study?
Does rosiglitazone reduce atrial structural remodeling and AF promotion in alloxan-induced diabetic rabbits?
Population
30 rabbits (20 alloxan-induced diabetic rabbits, 10 healthy controls)
Comparison
Rosiglitazone 2 mg/day/kg for 4 weeks vs Nontreated diabetic rabbits and healthy controls
Design
Preclinical, randomly divided
Follow-up
4 weeks
Authors
Loading...
Rosiglitazone attenuates AF in diabetic rabbits; leaves open translation to human therapy pending clinical trials.
Does rosiglitazone reduce atrial structural remodeling and AF promotion in alloxan-induced diabetic rabbits?
Rosiglitazone attenuates arrhythmogenic atrial structural remodeling and AF promotion in a diabetic rabbit model, potentially by modulating oxidative stress and inflammation.
Liu et al. (2014) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: